Literature DB >> 7930733

Antifungal activity of elutriated human monocytes against Aspergillus fumigatus hyphae: enhancement by granulocyte-macrophage colony-stimulating factor and interferon-gamma.

E Roilides1, A Holmes, C Blake, D Venzon, P A Pizzo, T J Walsh.   

Abstract

Human monocytes are important effector cells in host defenses against Aspergillus hyphae, and as elutriated monocytes (EHM) they may be transfused in large quantities to leukopenic patients with invasive aspergillosis. The antifungal activity of EHM against Aspergillus hyphae was compared with that of polymorphonuclear leukocytes (PMNL). The effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) and interferon-gamma (IFN-gamma) on superoxide anion (O2-) release and on hyphal damage caused by EHM against unopsonized A. fumigatus hyphae was investigated. EHM had antihyphal activity comparable to that of PMNL. GM-CSF significantly augmented O2- release by EHM in response to PMA. Also, both GM-CSF and IFN-gamma significantly enhanced the antifungal activity of EHM compared with untreated controls. Thus, EHM have demonstrable antifungal activity against Aspergillus hyphae that may be increased by GM-CSF and IFN-gamma, suggesting their potential therapeutic role in immune reconstitution of effector cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7930733     DOI: 10.1093/infdis/170.4.894

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  26 in total

Review 1.  Innate immunity to Aspergillus species.

Authors:  Stacy J Park; Borna Mehrad
Journal:  Clin Microbiol Rev       Date:  2009-10       Impact factor: 26.132

2.  Role of Granulocyte-Macrophage Colony-Stimulating Factor Signaling in Regulating Neutrophil Antifungal Activity and the Oxidative Burst During Respiratory Fungal Challenge.

Authors:  Shinji Kasahara; Anupam Jhingran; Sourabh Dhingra; Anand Salem; Robert A Cramer; Tobias M Hohl
Journal:  J Infect Dis       Date:  2016-02-09       Impact factor: 5.226

Review 3.  Haemopoietic colony stimulating factors for preterm neonates.

Authors:  R Carr; N Modi
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1997-03       Impact factor: 5.747

4.  In vitro activity of SCH-56592 and comparison with activities of amphotericin B and itraconazole against Aspergillus spp.

Authors:  K L Oakley; C B Moore; D W Denning
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

Review 5.  Impact of HIF-1α and hypoxia on fungal growth characteristics and fungal immunity.

Authors:  Dirk Friedrich; Roger A Fecher; Jan Rupp; George S Deepe
Journal:  Microbes Infect       Date:  2016-10-31       Impact factor: 2.700

Review 6.  Aspergillus fumigatus and aspergillosis.

Authors:  J P Latgé
Journal:  Clin Microbiol Rev       Date:  1999-04       Impact factor: 26.132

7.  Granulocyte macrophage colony-stimulating factor in 66 patients with myeloid or lymphoid neoplasms and recipients of hematopoietic stem cell transplantation with invasive fungal disease.

Authors:  Amar Safdar; Gilhen Rodriguez; Jorge Zuniga; Fadi Al Akhrass; Georgia Georgescu; Anupam Pande
Journal:  Acta Haematol       Date:  2012-10-02       Impact factor: 2.195

8.  Intranasal granulocyte-macrophage colony-stimulating factor reduces the Aspergillus burden in an immunosuppressed murine model of pulmonary aspergillosis.

Authors:  Gerardo Quezada; Nadezhda V Koshkina; Patrick Zweidler-McKay; Zichao Zhou; Dimitrios P Kontoyiannis; Eugenie S Kleinerman
Journal:  Antimicrob Agents Chemother       Date:  2007-11-05       Impact factor: 5.191

9.  Immunomodulation Therapy for Invasive Aspergillosis: Discussion on Myeloid Growth Factors, Recombinant Cytokines, and Antifungal Drug Immune Modulation.

Authors:  Amar Safdar
Journal:  Curr Fungal Infect Rep       Date:  2010-03

10.  Human phagocytic cell responses to Scedosporium apiospermum (Pseudallescheria boydii): variable susceptibility to oxidative injury.

Authors:  Cristina Gil-Lamaignere; Emmanuel Roilides; Caron A Lyman; Maria Simitsopoulou; Theodouli Stergiopoulou; Avgi Maloukou; Thomas J Walsh
Journal:  Infect Immun       Date:  2003-11       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.